内部控制评价报告的核查意见 华泰联合证券有限责任公司 关于广东众生药业股份有限公司 2024 年度内部控制评价报告的核查意见 华泰联合证券有限责任公司（以下简称"华泰联合"）作为广东众生药业股 份有限公司（以下简称"众生药业"、"公司"或"发行人"）向特定对象发行股 票的保荐机构，根据《证券发行上市保荐业务管理办法》《深圳证券交易所上市 公司自律监管指引第 1 号——主板上市公司规范运作》等文件的要求，华泰联合 对众生药业 2024 年度内部控制制度等相关事项进行核查，并发表独立意见如下： 一、众生药业内部控制的基本情况 （一）内部控制环境 众生药业自成立以来，根据国家有关法律、法规的要求，本着规范法人治理 的原则，逐步建立健全公司内部组织机构和各项内部控制制度。 公司设立了股东大会、董事会、监事会等相互约束的法人治理结构，并分别 设立了审计部、人力资源部、财务部等内部经营管理部门。公司各职能部门能够 按照公司制订的管理制度，在管理层的领导下规范运作。公司已形成了与公司实 际情况相适应的、有效的经营运作模式，组织机构分工明确、职能健全清晰，与 股东不存在任何隶属关系。 公司设立监事会，监事会是公司的内部监督机 ...

证券代码：002317 独立董事述职报告 本人牟小容，硕士研究生，注册会计师，注册税务师。现任华南农业大学经 管学院教师，副教授，硕士生导师。2022 年 12 月起任众生药业第八届董事会独 立董事。兼任广州康盛生物科技股份有限公司及广东原尚物流股份有限公司独立 董事、广州亨龙智能装备股份有限公司监事。 本人符合相关法律法规、监管规章关于上市公司独立董事任职资格条件的规 定，已由深圳证券交易所备案审查。 （二）不存在影响独立性的情况 广东众生药业股份有限公司 独立董事 2024 年度述职报告 各位股东及股东代表： 作为广东众生药业股份有限公司（以下简称"公司、众生药业"）的独立董 事，根据《公司法》《上市公司独立董事管理办法》等相关法律、法规以及《公 司章程》《独立董事工作制度》等的规定，本人忠实勤勉履行职责，充分发挥独 立董事的作用，维护公司整体利益和全体股东尤其是中小股东的合法权益。现将 本人 2024 年度履行独立董事职责情况汇报如下： 本人作为众生药业的独立董事，具备《上市公司独立董事管理办法》《深圳 证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》《公司章 程》及《公司独立董事工作 ...

证券代码：002317 独立董事述职报告 广东众生药业股份有限公司 独立董事 2024 年度述职报告 各位股东及股东代表： 作为广东众生药业股份有限公司（以下简称"公司、众生药业"）的独立董 事，根据《公司法》《上市公司独立董事管理办法》等相关法律、法规以及《公 司章程》《独立董事工作制度》等的规定，本人忠实勤勉履行职责，充分发挥独 立董事的作用，维护公司整体利益和全体股东尤其是中小股东的合法权益。现将 本人 2024 年度履行独立董事职责情况汇报如下： 一、基本情况 （一）工作履历、专业背景以及兼职情况 本人林瑞超，博士学历。曾任北京中医药大学教师，法国第戎大学教师，中 国药品生物制品检定所中药民族药检测中心研究员，中国食品药品检定研究院中 药民族药检定所研究员，葵花药业集团股份有限公司独立董事，现任北京中医药 大学中药学院教师，2022 年 12 月起任众生药业第八届董事会独立董事。兼任黑 龙江珍宝岛药业股份有限公司独立董事、北京博智绿洲医药科技有限公司董事、 普洱云河茶业有限公司董事。 本人符合相关法律法规、监管规章关于上市公司独立董事任职资格条件的规 定，已由深圳证券交易所备案审查。 （二）不存在影响 ...

证券代码：002317 独立董事述职报告 广东众生药业股份有限公司 独立董事 2024 年度述职报告 各位股东及股东代表： 作为广东众生药业股份有限公司（以下简称"公司、众生药业"）的独立董 事，根据《公司法》《上市公司独立董事管理办法》等相关法律、法规以及《公 司章程》《独立董事工作制度》等的规定，本人忠实勤勉履行职责，充分发挥独 立董事的作用，维护公司整体利益和全体股东尤其是中小股东的合法权益。现将 本人 2024 年度履行独立董事职责情况汇报如下： 本人符合相关法律法规、监管规章关于上市公司独立董事任职资格条件的规 定，已由深圳证券交易所备案审查。 （二）不存在影响独立性的情况 本人作为众生药业的独立董事，具备《上市公司独立董事管理办法》《深圳 证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》《公司章 程》及《公司独立董事工作制度》所要求的独立性，并按照监管规则进行了独立 性自查，确认已满足适用的各项监管规定中对于出任公司独立董事所应具备的独 1 证券代码：002317 独立董事述职报告 一、基本情况 （一）工作履历、专业背景以及兼职情况 本人吴清功，硕士。曾任北京和君咨询有限公司合伙 ...

广东众生药业股份有限公司 第八届董事会独立董事专门会议 2025 年第三次会议审核意见 根据《上市公司独立董事管理办法》《深圳证券交易所股票上市规则》《深圳 证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等相关法 律法规及规范性文件的有关规定，广东众生药业股份有限公司（以下简称"公司"） 第八届董事会独立董事专门会议 2025 年第三次会议于 2025 年 4 月 24 日在公司 会议室以现场方式召开。本次会议应出席独立董事3人，实际出席独立董事3人。 经全体独立董事推举，本次会议由独立董事牟小容女士召集并主持。全体独立董 事本着认真、负责的态度，对公司相关议案及事项进行了审议并发表审核意见如 下： 一、会议以 3 票同意， 0 票反对，0 票弃权的表决结果，审议通过了《关于 <公司 2024 年度内部控制评价报告>的议案》。 公司内部控制制度符合法律、法规及《公司章程》的相关规定，适应当前公 司生产经营实际情况的需要，并能够得到有效的执行。《公司 2024 年度内部控制 评价报告》真实、客观反映了公司内控制度的建设与运行情况。 二、会议以 3 票同意， 0 票反对，0 票弃权的表决结果， ...

（二）社会上存在的已经或将给公司造成不良影响的传言或信息。 证券代码：002317 舆情管理制度 （三）可能或者已经影响社会公众投资者投资取向，造成股价异常波动的信 息。 广东众生药业股份有限公司 舆情管理制度 第一章 总则 第一条 为了提高广东众生药业股份有限公司（以下简称"公司"）应对各 类舆情的能力，建立快速反应和应急处置机制，及时、妥善处理各类舆情对公司 股价、公司商业信誉及正常生产经营活动造成的影响，切实保护投资者合法权益， 公司根据相关法律法规和《公司章程》的规定，结合公司实际情况，制定本制度。 第二条 本制度所称舆情包括： （一）报刊、杂志、电视、广播、网络等媒体对公司进行的负面报道。 （四）其他涉及公司信息披露且可能对公司股票及其衍生品交易价格产生较 大影响的事件信息。 第三条 舆情信息的分类： （一）重大舆情：指传播范围较广，严重影响公司公众形象或正常经营活动， 使公司已经或可能遭受损失，已经或可能造成公司股票及其衍生品种交易价格变 动的负面舆情。 （二）一般舆情：指除重大舆情之外的其他舆情。 第四条 本制度适用于公司及合并报表范围内的子公司（以下简称"子公司"）。 第二章 舆情管理的组织体 ...

广东众生药业股份有限公司董事会 董事会对独立董事独立性自查情况的专项意见 二〇二五年四月二十四日 根据《上市公司独立董事管理办法》《深圳证券交易所股票上市规则》《深圳 证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》等的规 定，广东众生药业股份有限公司（以下简称"公司"）董事会，就公司在任独立 董事牟小容女士、林瑞超先生、吴清功先生的独立性情况进行评估并出具如下专 项意见： 证券代码：002317 专项意见 广东众生药业股份有限公司 经核查独立董事牟小容女士、林瑞超先生、吴清功先生的任职经历以及签署 的相关文件，上述人员未在公司担任除独立董事以外的任何职务，也未在公司主 要股东公司担任任何职务，与公司以及公司主要股东、实际控制人之间不存在利 害关系或其他可能妨碍其进行独立客观判断的关系，不存在影响独立董事独立性 的情况，符合《上市公司独立董事管理办法》《深圳证券交易所上市公司自律监 管指引第 1 号——主板上市公司规范运作》中对独立董事独立性的相关要求。 第 1 页 共 1 页 ...

二、前10名无限售条件股东持股情况 前十大流通股东累计持有： 18747.58万股，累计占流通股比： 24.62%，较上期变化： -972.38万股。 | 名称 | 持有数量(万股) | 占总股本比 | 增减情况 | | --- | --- | --- | --- | | | | 例(%) | (万股) | | 张玉立 | 9264.05 | 12.16 | 不变 | | 张玉冲 | 2316.01 | 3.04 | 不变 | | 全国社保基金六零四组合 | 2000.02 | 2.63 | -452.65 | | 龙超峰 | 887.62 | 1.17 | 不变 | | 叶惠棠 | 812.52 | 1.07 | 10.50 | | 李煜坚 | 800.00 | 1.05 | 不变 | | 上海银行（601229）股份有限公司-银华中创新药产业交易 型开放式指数证券投资基金 | 776.60 | 1.02 | 新进 | | 中国银行股份有限公司-兴全合丰三年持有期混合型证券投 资基金 | 724.39 | 0.95 | 新进 | | 中国建设银行股份有限公司-兴全多维价值混合型证券投资 | | | | | ...

Financial Performance - The company's operating revenue for 2024 was CNY 2,467,418,394.64, a decrease of 5.48% compared to CNY 2,610,550,120.98 in 2023[18] - The net profit attributable to shareholders for 2024 was CNY -299,157,116.72, representing a decline of 213.63% from CNY 263,273,179.73 in 2023[18] - The basic earnings per share for 2024 was CNY -0.36, a decrease of 212.50% from CNY 0.32 in 2023[18] - The company reported a significant increase in the net profit after deducting non-recurring gains and losses, which was CNY -260,312,696.31 in 2024, down 185.41% from CNY 304,777,222.28 in 2023[18] - The weighted average return on net assets for 2024 was -7.24%, a decrease of 13.82% from 6.58% in 2023[18] - The company acknowledged uncertainties regarding its ability to continue as a going concern due to negative net profits in the recent accounting periods[18] Cash Flow and Investments - The net cash flow from operating activities increased by 77.24% to CNY 337,842,262.04 in 2024, compared to CNY 190,613,632.04 in 2023[18] - The company reported a significant increase in investment activity cash inflow, which rose by 270.30% to CNY 1,593,659,455.39 in 2024 from CNY 430,369,798.46 in 2023[91] - The cash flow from financing activities showed a significant decline, with a net outflow of CNY -562,171,817.13 in 2024 compared to a net inflow of CNY 841,717,750.30 in 2023, marking a decrease of 166.79%[91] - The company has obtained drug registration certificates for multiple products, which is expected to positively impact market share and future sales, although uncertainties remain regarding production and sales[88] Research and Development - The company has invested over 10% of its annual revenue in R&D for the past three years, with a total R&D team exceeding 400 members[48] - The total R&D expenditure decreased by 19.28% to CNY 263,460,034.52 in 2024 from CNY 326,396,807.54 in 2023, with the R&D expenditure as a percentage of operating revenue dropping to 10.68% from 12.50%[89] - The company is focusing on the development of innovative drugs for metabolic and respiratory diseases, with significant progress in clinical trials and regulatory approvals[44] - The company has established a multi-mode R&D ecosystem focusing on independent research and development, supplemented by collaborative efforts to meet significant clinical needs[40] - The company is committed to exploring new drug development and revitalizing dormant products, leveraging policy opportunities for growth[35] Market and Industry Trends - The pharmaceutical industry is experiencing a shift towards innovation-driven growth, supported by government policies and technological advancements[28] - In 2024, over 270 national-level policies and approximately 1300 provincial-level policies related to the pharmaceutical industry were released, creating a favorable external environment for industry development[29] - The total revenue of the pharmaceutical manufacturing industry in China for 2024 was ¥2,529.85 billion, showing no growth compared to the previous year[28] - The total profit of the pharmaceutical manufacturing industry decreased by 1.1% year-on-year to ¥342.07 billion in 2024[28] Product Development and Innovation - The company focuses on innovative drug research and development in metabolic and respiratory diseases, maintaining a leading position domestically[33] - The company’s innovative drug, Lai Ru Te Wei Tablets, is the world's first oral drug targeting COVID-19, included in the expert consensus for clinical application in 2024[36] - The company has a robust product pipeline and actively expands sales channels, including online sales and third-party terminals, to enhance market reach[34] - The company’s products cover major disease areas such as cardiovascular, respiratory, ophthalmology, and digestive diseases, with a continuous optimization of product structure[32] - The company is committed to the internationalization of its innovative drugs, supported by government policies that enhance R&D and market application[119] Corporate Governance and Investor Relations - The company has established a comprehensive investor relations management system[139] - The company has taken effective measures to protect the legal rights of investors[137] - The company emphasizes investor relations, implementing various communication methods, including performance briefings and dedicated investor hotlines, to enhance transparency and engagement[143] - The company has established a transparent performance evaluation system for directors and senior management, linking their compensation to company performance and individual achievements[144] - The company has implemented a cash repurchase program as part of its strategy to return value to shareholders[142] Strategic Planning and Future Outlook - The company plans to enhance its market position by focusing on innovative drug development and optimizing its product pipeline in response to national policies promoting the biopharmaceutical industry[113] - The company aims to solidify its core prescription drug business and face new challenges by 2025[126] - The company is expected to continue its growth trajectory with strategic management changes and a focus on market expansion[152] - The company plans to enhance production capacity and supply chain operations, aiming for refined management of quality, efficiency, and costs in its manufacturing sector[129] - The company is actively pursuing strategic adjustments across R&D, production, and sales to enhance competitiveness in a slowing industry environment[41] Employee and Talent Management - The total number of employees at the end of the reporting period was 1,775, with 714 in the parent company and 1,061 in major subsidiaries[176] - The company emphasizes talent development through structured training plans for different employee levels, ensuring a robust talent pipeline[181] - The annual training plan focuses on enhancing professional skills and knowledge, with quarterly legal training sessions for key personnel[179] - The company has established a "Five-Star Team" evaluation standard to improve production efficiency and team management, with assessments conducted quarterly[180] - The company has implemented a tiered salary mechanism based on functional contributions, ensuring internal fairness and external competitiveness in compensation[178]

Financial Performance - The company's revenue for Q1 2025 was CNY 634,261,440.11, a decrease of 1.07% compared to the same period last year[5] - Net profit attributable to shareholders increased by 61.06% to CNY 82,611,839.10 compared to the previous year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 78,434,825.55, an increase of 8.60% year-on-year[5] - Basic and diluted earnings per share rose by 66.67% to CNY 0.10 per share[5] - Net profit for the current period is ¥81,448,217.01, an increase of 67.24% compared to ¥48,710,926.21 in the previous period[24] - Comprehensive income for the current period is ¥78,613,417.36, compared to ¥49,316,011.34 in the previous period, an increase of 59.53%[25] Cash Flow - The net cash flow from operating activities improved by 63.98%, reaching CNY -28,614,967.91[5] - The net cash flow from operating activities was -$28.61 million, an improvement from -$79.45 million in the previous period[27] - Cash inflow from operating activities totaled ¥412,758,125.62, down from ¥438,885,971.29, a decrease of 5.95%[26] - The net cash flow from investing activities decreased by 79.66% to ¥18,041,267.34, primarily due to changes in the purchase and recovery of bank deposit products during the reporting period[11] - The net cash flow from financing activities decreased by 34.68% to -¥397,557,854.76, mainly due to payments for share buybacks and the repayment of bank loans in the same period last year[11] - The net cash flow from investment activities was $18.04 million, a decrease from $88.72 million year-over-year[27] - The net cash flow from financing activities was -$397.56 million, worsening from -$295.20 million in the previous period[27] Assets and Liabilities - Total assets decreased by 5.78% to CNY 5,232,775,325.09 compared to the end of the previous year[5] - As of March 31, 2025, the total assets of the company amounted to RMB 5.23 billion, a decrease from RMB 5.55 billion at the beginning of the period[22] - The company’s total liabilities decreased from RMB 1.54 billion to RMB 1.14 billion, reflecting a significant reduction in financial obligations[22] - Current assets totaled RMB 3.14 billion, down from RMB 3.46 billion, indicating a decline in liquidity[21] - Cash and cash equivalents decreased from RMB 1.40 billion to RMB 990.26 million, showing a reduction in available cash[20] - The company’s short-term borrowings increased from RMB 303.46 million to RMB 353.26 million, indicating a rise in short-term debt[22] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 91,109[14] - The company’s major shareholders, Zhang Yuchong and Zhang Yuli, each hold 10.88% of the shares, with significant portions pledged[14] Research and Development - Research and development expenses decreased by 46.87% to ¥15,923,565.59, mainly due to the large external research progress payments made in the same period last year[11] - Research and development expenses decreased significantly to ¥15,923,565.59 from ¥29,971,407.45, a reduction of 46.94%[23] - The company’s subsidiary, Guangdong South China Pharmaceutical Group, received approval for its brain embolism capsule as the first secondary protected traditional Chinese medicine, with a protection period of seven years starting from the announcement date[15] - The company’s subsidiary, Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd., received FDA approval for the clinical trial of the innovative peptide drug RAY1225, which targets obesity and type 2 diabetes[16] - RAY1225 is set to enter Phase III clinical trials, with ethical approval obtained from key institutions, indicating significant progress in its development[16] Other Income and Expenses - Other income increased by 182.18% to ¥9,079,567.10, attributed to an increase in government subsidies received during the reporting period[11] - Tax expenses rose to ¥17,814,054.06 from ¥10,405,699.02, an increase of 71.00%[24] - Sales expenses increased to ¥218,567,447.02 from ¥213,627,193.97, an increase of 2.18%[23] Strategic Focus - The company aims to enhance operational efficiency and profitability through strategic focus on core business segments and cost control upgrades in 2025[9] - The company reported a significant improvement in operational indicators, laying a foundation for high-quality development throughout the year[9] Accounting and Audit - The company did not undergo an audit for the first quarter report[28] - The new accounting standards will be implemented starting in 2025[28]